Sign in

CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Rapport Therapeutics, Inc.

Sign in to watch
Ticker
RAPP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
880724208
Phone
857-321-8020
Business address
99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
Former names
Rapport Therapeutics, Inc.
  1. 4 Open-market buy Director bought 20,400 shares at $24.48 ($499,374)
  2. 4 Open-market buy Director bought 41,666 shares at an average $24.65 ($1,027,111)
  3. 4 Open-market buy Director bought 3,500 shares at $22.60 ($79,100)
  4. 4 Planned sale Chief Operating Officer sold 5,000 shares at $38.33 ($191,650)
  5. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $15.00 ($127,466)
  6. 4 Planned sale Chief Scientific Officer sold 8,500 shares at $14.00 ($118,962)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Planned sale Chief Scientific Officer sold 8,500 shares at $11.00 ($93,522)
  15. 4 Derivatives Options or other derivatives
  16. 4 Planned sale Chief Scientific Officer sold 8,500 shares at $9.56 ($81,262)
  17. 4 Planned sale Chief Scientific Officer sold 8,500 shares at $9.57 ($81,310)
  18. 4 Derivatives Options or other derivatives
  19. 4 Planned sale Chief Scientific Officer sold 8,500 shares at $10.85 ($92,205)
  20. 4 Open-market buy Chief Financial Officer bought 10,000 shares at an average $10.10 ($100,988)

Page 4 of 6 · 120 filings